Despite the difficulties in finding funding in the first rounds, the number of operations and stakeholders interested in participating continues a clear upward trend.
The main current challenges for biotechnology-based companies are (1) the high financing required to reach the market, (2) long waiting times and (3) the low probability of success, considering the large amount of biotechnological knowledge generated every day.
In addition, the business management of the knowledge generated in the laboratory usually requires the advice of experts in the sector who, in addition, focus on the traction and commercial development of the company, also including a financial perspective.
Small and medium-sized companies related to Life Sciences, fundamentally those based on biotechnology, are currently on the frontier of knowledge to innovate in the search for new treatments against diseases that are often incurable such as many types of cancers, neurodegenerative diseases or autoimmune.
Promoter of the most innovative and disruptive concept to which current medicine tends, that of "personalized and precision medicine"
The extreme capacity for customization and specificity of treatments based on it (biosimilar drugs, biomarkers, genetic targets …), compared to the non-specificity of those based on chemical synthesis.
Provides a holistic view of the patient thanks to the knowledge of omics sciences
Detailed knowledge of individuals from the molecular perspective: genomics, epigenomics, transcriptomics, metabolomics, microbiomics and metagenomics …
Speed of economic value creation from discovery
We are in a historic moment, since some discoverers of biomedical technology, such as those of CRISPR Technology (precision gene editing) or Yamanaka Factors (proteins that rejuvenate cells to literally embryonic stages), have become the winners of Nobel Laureates (in Chemistry in 2020, and in Physiology and Medicine in 2012, respectively) with the shortest time elapsed between the discovery and the awarding of the prize, in the entire history of the Swedish Academy of Sciences. Both technologies are in different stages of clinical validation.
Current relevance in next-generation treatments
70% of the clinical trials carried out today are based on biotechnology and there are more than 300 therapies in the last phase.
The range of possibilities is very wide.
Gene and cell therapy, combinatorial biosynthesis of complex drugs, antibody generation, recombinant proteins, nucleic acid therapy, vector design …
We work to be your reference in strategic consultancy in new technologies technologies in the Health Sector.
We offer consultancy in process re-engineering based on technology and in the technology and in analysis of the value of companies for investment decisions. investment decisions.
Schedule a consultation
You can request a meeting to share your project and needs with us.
